DYNACIRC Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Dynacirc, and what generic alternatives are available?

Dynacirc is a drug marketed by Smithkline Beecham and Glaxosmithkline Llc and is included in two NDAs.

The generic ingredient in DYNACIRC is isradipine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the isradipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dynacirc

A generic version of DYNACIRC was approved as isradipine by WATSON LABS TEVA on January 5^th, 2006.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for DYNACIRC?
What are the global sales for DYNACIRC?
What is Average Wholesale Price for DYNACIRC?

Summary for DYNACIRC

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	3
Patent Applications:	5,631
DailyMed Link:	DYNACIRC at DailyMed

Drug patent expirations by year for DYNACIRC

Recent Clinical Trials for DYNACIRC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Drug Abuse (NIDA)	Early Phase 1
University of Texas at Austin	Early Phase 1
Northwestern University Dixon Fund	Phase 2

See all DYNACIRC clinical trials

US Patents and Regulatory Information for DYNACIRC

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Smithkline Beecham	DYNACIRC	isradipine	CAPSULE;ORAL	019546-001	Dec 20, 1990		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-002	Jun 1, 1994		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Smithkline Beecham	DYNACIRC	isradipine	CAPSULE;ORAL	019546-002	Dec 20, 1990		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-001	Jun 1, 1994		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for DYNACIRC

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Smithkline Beecham	DYNACIRC	isradipine	CAPSULE;ORAL	019546-001	Dec 20, 1990	⤷ Sign Up	⤷ Sign Up
Smithkline Beecham	DYNACIRC	isradipine	CAPSULE;ORAL	019546-002	Dec 20, 1990	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for DYNACIRC

See the table below for patents covering DYNACIRC around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Australia	6460380		⤷ Sign Up
Kenya	3593	A 1,4-DIHYDROPYRIDINE DERIVATIVE ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT	⤷ Sign Up
United Kingdom	2037766	1,4-DIHYDROPYRIDINES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	⤷ Sign Up
New Zealand	192422	BENZOXADIAZOLES AND BENZOTHIADIAZOLES WITH 1,4-DIHYDROPYRIDINE MOIETY PHARMACEUTICAL COMPOSITIONS	⤷ Sign Up
Ireland	781231		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for DYNACIRC

Recent Clinical Trials for DYNACIRC

Make Better Decisions: Try a trial or see plans & pricing